{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:26:22Z","timestamp":1793305582909,"version":"4.5.0"},"reference-count":61,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Agency for Medical Research and Development","award":["JP22ama121008"],"award-info":[{"award-number":["JP22ama121008"]}]},{"name":"Japan Agency for Medical Research and Development","award":["JP22am0401013"],"award-info":[{"award-number":["JP22am0401013"]}]},{"name":"Japan Agency for Medical Research and Development","award":["JP22bm1004001"],"award-info":[{"award-number":["JP22bm1004001"]}]},{"name":"Japan Agency for Medical Research and Development","award":["JP22ck0106730"],"award-info":[{"award-number":["JP22ck0106730"]}]},{"name":"Japan Agency for Medical Research and Development","award":["JP21am0101078"],"award-info":[{"award-number":["JP21am0101078"]}]},{"name":"Japan Agency for Medical Research and Development","award":["21K20789"],"award-info":[{"award-number":["21K20789"]}]},{"name":"Japan Agency for Medical Research and Development","award":["22K06995"],"award-info":[{"award-number":["22K06995"]}]},{"name":"Japan Agency for Medical Research and Development","award":["21K07168"],"award-info":[{"award-number":["21K07168"]}]},{"name":"Japan Agency for Medical Research and Development","award":["22K07224"],"award-info":[{"award-number":["22K07224"]}]},{"name":"Japan Society for the Promotion of Science","award":["JP22ama121008"],"award-info":[{"award-number":["JP22ama121008"]}]},{"name":"Japan Society for the Promotion of Science","award":["JP22am0401013"],"award-info":[{"award-number":["JP22am0401013"]}]},{"name":"Japan Society for the Promotion of Science","award":["JP22bm1004001"],"award-info":[{"award-number":["JP22bm1004001"]}]},{"name":"Japan Society for the Promotion of Science","award":["JP22ck0106730"],"award-info":[{"award-number":["JP22ck0106730"]}]},{"name":"Japan Society for the Promotion of Science","award":["JP21am0101078"],"award-info":[{"award-number":["JP21am0101078"]}]},{"name":"Japan Society for the Promotion of Science","award":["21K20789"],"award-info":[{"award-number":["21K20789"]}]},{"name":"Japan Society for the Promotion of Science","award":["22K06995"],"award-info":[{"award-number":["22K06995"]}]},{"name":"Japan Society for the Promotion of Science","award":["21K07168"],"award-info":[{"award-number":["21K07168"]}]},{"name":"Japan Society for the Promotion of Science","award":["22K07224"],"award-info":[{"award-number":["22K07224"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Gastric cancer (GC) is the third leading cause of cancer-related deaths worldwide. GC with peritoneal metastasis exhibits a poor prognosis due to the lack of effective therapy. A comprehensive analysis of malignant ascites identified the genomic alterations and significant amplifications of cancer driver genes, including CD44. CD44 and its splicing variants are overexpressed in tumors, and play crucial roles in the acquisition of invasiveness, stemness, and resistance to treatments. Therefore, the development of CD44-targeted monoclonal antibodies (mAbs) is important for GC diagnosis and therapy. In this study, we immunized mice with CD44v3\u201310-overexpressed PANC-1 cells and established several dozens of clones that produce anti-CD44v3\u201310 mAbs. One of the clones (C44Mab-94; IgG1, kappa) recognized the variant-8-encoded region and peptide, indicating that C44Mab-94 is a specific mAb for CD44v8. Furthermore, C44Mab-94 could recognize CHO\/CD44v3\u201310 cells, oral squamous cell carcinoma cell line (HSC-3), or GC cell lines (MKN45 and NUGC-4) in flow cytometric analyses. C44Mab-94 could detect the exogenous CD44v3\u201310 and endogenous CD44v8 in western blotting and stained the formalin-fixed paraffin-embedded gastric cancer cells. These results indicate that C44Mab-94 is useful for detecting CD44v8 in a variety of experimental methods and is expected to become usefully applied to GC diagnosis and therapy.<\/jats:p>","DOI":"10.3390\/antib12030045","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:37:28Z","timestamp":1688517448000},"page":"45","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5132","authenticated-orcid":false,"given":"Hiroyuki","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"},{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nohara","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunenori","family":"Ouchida","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika K.","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"},{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-8201","authenticated-orcid":false,"given":"Yukinari","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"},{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"103841","DOI":"10.1016\/j.critrevonc.2022.103841","article-title":"Characteristics of gastric cancer around the world","volume":"181","author":"Carbajal","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","article-title":"The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification","volume":"64","author":"Lauren","year":"1965","journal-title":"Acta Pathol. Microbiol. Scand."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00292-021-01023-7","article-title":"The updated WHO classification of digestive system tumours-gastric adenocarcinoma and dysplasia","volume":"43","author":"Kushima","year":"2022","journal-title":"Pathologe"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 513, 202\u2013209.","DOI":"10.1038\/nature13480"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"188719","DOI":"10.1016\/j.bbcan.2022.188719","article-title":"Diffuse gastric cancer: Emerging mechanisms of tumor initiation and progression","volume":"1877","author":"Monster","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s43018-021-00240-6","article-title":"Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities","volume":"2","author":"Tanaka","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","article-title":"Mechanisms of Therapeutic Antitumor Monoclonal Antibodies","volume":"81","author":"Tsao","year":"2021","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0092-8674(91)90403-L","article-title":"A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells","volume":"65","author":"Hofmann","year":"1991","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1004","article-title":"CD44: From adhesion molecules to signalling regulators","volume":"4","author":"Ponta","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.5966\/sctm.2015-0048","article-title":"Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target","volume":"4","author":"Yan","year":"2015","journal-title":"Stem Cells Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","article-title":"The biology and role of CD44 in cancer progression: Therapeutic implications","volume":"11","author":"Chen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"883831","DOI":"10.3389\/fonc.2022.883831","article-title":"CD44 Glycosylation as a Therapeutic Target in Oncology","volume":"12","author":"Liao","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/jomfp.JOMFP_246_18","article-title":"Structure, function and role of CD44 in neoplasia","volume":"23","author":"Mishra","year":"2019","journal-title":"J. Oral Maxillofac. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.matbio.2006.08.261","article-title":"Hyaluronan-mediated angiogenesis in vascular disease: Uncovering RHAMM and CD44 receptor signaling pathways","volume":"26","author":"Slevin","year":"2007","journal-title":"Matrix Biol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hassn Mesrati, M., Syafruddin, S.E., Mohtar, M.A., and Syahir, A. (2021). CD44: A Multifunctional Mediator of Cancer Progression. Biomolecules, 11.","DOI":"10.3390\/biom11121850"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7970","DOI":"10.1111\/febs.16179","article-title":"The state of CD44 activation in cancer progression and therapeutic targeting","volume":"289","author":"Guo","year":"2021","journal-title":"FEBS J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc3023","article-title":"CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule?","volume":"11","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1083\/jcb.128.4.673","article-title":"Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon","volume":"128","author":"Jackson","year":"1995","journal-title":"J. Cell Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1083\/jcb.128.4.687","article-title":"CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor","volume":"128","author":"Bennett","year":"1995","journal-title":"J. Cell Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.1128\/MCB.01355-07","article-title":"Haploinsufficiency of c-Met in cd44\u2212\/\u2212 mice identifies a collaboration of CD44 and c-Met in vivo","volume":"27","author":"Matzke","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1101\/gad.242602","article-title":"CD44 is required for two consecutive steps in HGF\/c-Met signaling","volume":"16","author":"Chen","year":"2002","journal-title":"Genes Dev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2011.01.038","article-title":"CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc\u2212 and thereby promotes tumor growth","volume":"19","author":"Ishimoto","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hagiwara, M., Kikuchi, E., Tanaka, N., Kosaka, T., Mikami, S., Saya, H., and Oya, M. (2018). Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-3988-3"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"34876","DOI":"10.18632\/oncotarget.26172","article-title":"High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy","volume":"9","author":"Kagami","year":"2018","journal-title":"Oncotarget"},{"key":"ref_29","first-page":"64","article-title":"Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C44Mab-5","volume":"14","author":"Yamada","year":"2018","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Goto, N., Suzuki, H., Tanaka, T., Asano, T., Kaneko, M.K., and Kato, Y. (2022). Development of a Novel Anti-CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105535"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/mab.2021.0028","article-title":"Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C44Mab-46) Using Alanine-Scanning Mutagenesis and Surface Plasmon Resonance","volume":"40","author":"Takei","year":"2021","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1089\/mab.2021.0023","article-title":"Development of a Novel Epitope Mapping System: RIEDL Insertion for Epitope Mapping Method","volume":"40","author":"Asano","year":"2021","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"ref_33","first-page":"1949","article-title":"A defucosylated antiCD44 monoclonal antibody 5mG2af exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma","volume":"44","author":"Takei","year":"2020","journal-title":"Oncol. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Suzuki, H., Tanaka, T., Goto, N., Kaneko, M.K., and Kato, Y. (2023). Development of a Novel Anti-CD44 Variant 4 Monoclonal Antibody C44Mab-108 for Immunohistochemistry. Curr. Issues Mol. Biol., 45.","DOI":"10.20944\/preprints202212.0392.v1"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kudo, Y., Suzuki, H., Tanaka, T., Kaneko, M.K., and Kato, Y. (2023). Development of a Novel Anti-CD44 variant 5 Monoclonal Antibody C44Mab-3 for Multiple Applications against Pancreatic Carcinomas. Antibodies, 12.","DOI":"10.20944\/preprints202301.0581.v1"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ejima, R., Suzuki, H., Tanaka, T., Asano, T., Kaneko, M.K., and Kato, Y. (2023). Development of a Novel Anti-CD44 Variant 6 Monoclonal Antibody C44Mab-9 for Multiple Applications against Colorectal Carcinomas. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24044007"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Suzuki, H., Ozawa, K., Tanaka, T., Kaneko, M.K., and Kato, Y. (2023). Development of a Novel Anti-CD44 Variant 7\/8 Monoclonal Antibody, C44Mab-34, for Multiple Applications against Oral Carcinomas. Biomedicines, 11.","DOI":"10.20944\/preprints202302.0437.v1"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Tawara, M., Suzuki, H., Goto, N., Tanaka, T., Kaneko, M.K., and Kato, Y. (2023). A Novel Anti-CD44 Variant 9 Monoclonal Antibody C44Mab-1 was Developed for Immunohistochemical Analyses Against Colorectal Cancers. Curr. Issues Mol. Biol., 45.","DOI":"10.20944\/preprints202303.0399.v1"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1111\/cas.15353","article-title":"CD44v3,8-10 is essential for Slug-dependent vimentin gene expression to acquire TGF-\u03b21-induced tumor cell motility","volume":"113","author":"Qiu","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.canlet.2019.10.010","article-title":"CD44(+) tumor cells promote early angiogenesis in head and neck squamous cell carcinoma","volume":"467","author":"Ludwig","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s002620050329","article-title":"Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas","volume":"43","author":"Heider","year":"1996","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/0959-8049(95)00420-3","article-title":"Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys","volume":"31","author":"Heider","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1097-0215(19960422)69:2<79::AID-IJC2>3.0.CO;2-S","article-title":"Increasing incidence of CD44v7\/8 epitope expression during uterine cervical carcinogenesis","volume":"69","author":"Dall","year":"1996","journal-title":"Int. J. Cancer"},{"key":"ref_44","first-page":"1125","article-title":"Expression of CD44 splice variants in normal, dysplastic, and neoplastic cervical epithelium","volume":"1","author":"Woerner","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"ref_45","first-page":"5499","article-title":"Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas","volume":"55","author":"Gansauge","year":"1995","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ijc.10369","article-title":"Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts","volume":"99","author":"Verel","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.oraloncology.2007.10.009","article-title":"Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma","volume":"44","author":"Riechelmann","year":"2008","journal-title":"Oral Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","article-title":"A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus","volume":"12","author":"Tijink","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_49","first-page":"4539","article-title":"Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms","volume":"54","author":"Fox","year":"1994","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/1873-3468.13432","article-title":"O-glycan truncation enhances cancer-related functions of CD44 in gastric cancer","volume":"593","author":"Mereiter","year":"2019","journal-title":"FEBS Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/bjc.2013.314","article-title":"CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence","volume":"109","author":"Hirata","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10120-016-0610-8","article-title":"Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)","volume":"20","author":"Shitara","year":"2017","journal-title":"Gastric. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3892\/ijmm.2023.5221","article-title":"Antitumor activities of a defucosylated anti-EpCAM monoclonal antibody in colorectal carcinoma xenograft models","volume":"51","author":"Li","year":"2023","journal-title":"Int. J. Mol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e1043","DOI":"10.1002\/ctm2.1043","article-title":"CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations","volume":"12","author":"Tang","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"eabg3072","DOI":"10.1126\/scitranslmed.abg3072","article-title":"Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies","volume":"14","author":"Greco","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fimmu.2020.00099","article-title":"CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice","volume":"11","author":"Porcellini","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"15444","DOI":"10.1073\/pnas.1506943112","article-title":"Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal","volume":"112","author":"Holm","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1038\/srep05924","article-title":"A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin","volume":"4","author":"Kato","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_59","first-page":"100826","article-title":"A cancer-specific anti-podocalyxin monoclonal antibody (60-mG2a-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma","volume":"24","author":"Kaneko","year":"2020","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Suzuki, H., Kaneko, M.K., and Kato, Y. (2022). Roles of Podoplanin in Malignant Progression of Tumor. Cells, 11.","DOI":"10.20944\/preprints202201.0280.v1"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.omto.2022.07.006","article-title":"Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47\u0394 combination therapy against glioblastoma","volume":"26","author":"Chalise","year":"2022","journal-title":"Mol. Ther.-Oncolytics"}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/12\/3\/45\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:06:13Z","timestamp":1760126773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/12\/3\/45"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":61,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["antib12030045"],"URL":"https:\/\/doi.org\/10.3390\/antib12030045","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]}}}